Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | September 06, 2024 | September 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date September 06, 2024 · Filed September 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,651 |
Reported balance
After 2024-09-06 transaction · row 1
1 source rowRow 1 · 2024-09-06 · Gift · Disposed 230,000 · Balance 35,651 |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2022 GRAT | 0 |
Reported balance
After 2024-09-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-09-06 · Gift · Disposed 302,179 · Balance 0 F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2024 GRAT | 419,574 |
Reported balance
After 2024-09-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-09-06 · Gift · Acquired 419,574 · Balance 419,574 F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Ayers Family Trust | 122,605 |
Reported balance
After 2024-09-06 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2024-09-06 · Gift · Acquired 112,605 · Balance 122,605 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 134 | $437.32 | $58,600.88 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,213 Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $440.23 | $44,023.00 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,467 Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 800 | $439.59 | $351,675.44 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,567 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $439.045 to a high of $439.83 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 400 | $438.54 | $175,417.00 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 754,367 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $438.01 to a high of $439.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $436.70 | $131,010.48 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 754,767 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $436.18 to a high of $437.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 773 | $435.53 | $336,662.45 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,067 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $435.17 to a high of $436.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,285 | $434.47 | $558,296.39 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,840 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $433.99 to a high of $434.88 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,015 | $433.42 | $439,921.71 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 757,125 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $432.96 to a high of $433.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 500 | $432.28 | $216,139.50 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758,140 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $431.815 to a high of $432.72 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,102 | $430.72 | $905,367.55 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758,640 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $430.42 to a high of $431.28 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:25 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,725 | $429.93 | $1,171,571.79 |
DisclosureSEC source: 0001567619-20-018702 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,742 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $429.39 to a high of $430.375 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $440.23 | $44,023.00 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,347 Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 800 | $439.59 | $351,675.44 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,447 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $439.045 to a high of $439.83 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 400 | $438.54 | $175,417.00 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,247 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $438.01 to a high of $439.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $436.70 | $131,010.48 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,647 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $436.18 to a high of $437.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 773 | $435.53 | $336,662.45 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,947 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $435.17 to a high of $436.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,285 | $434.47 | $558,296.39 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729,720 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $433.99 to a high of $434.88 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,015 | $433.42 | $439,921.71 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,005 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $432.96 to a high of $433.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 500 | $432.28 | $216,139.50 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,020 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $431.815 to a high of $432.72 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,102 | $430.72 | $905,367.55 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,520 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $430.42 to a high of $431.28 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,725 | $429.93 | $1,171,571.79 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,622 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $429.39 to a high of $430.375 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 26,120 | $424.82 | $11,096,298.40 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,347 F1 · shares: Shares withheld for the payment of taxes on the conversion of 14,791 deferred stock units ('DSUs') acquired pursuant to the IDEXX Laboratories, Inc. Executive Deferred Compensation Plan and which were reported previously on Table I and represented a right to receive one share of Issuer common stock without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on November 7, 2007 and on June 15, 2015 (the "Stock Splits"). The total number of securities previously reported as beneficially owned, as adjusted to reflect the Stock Splits, is 59,164 DSUs, which were converted to an equal number of shares of Issuer common stock one year following the reporting person's resignation as an executive from IDEXX Laboratories, Inc. Read SEC document |
| August 25, 2020 Filed Aug 28, 2020 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-016146 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,467 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,954 Underlying: Common Stock · 18,000 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 500 | $384.57 | $192,285.00 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,467 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,634 | $383.78 | $1,010,865.19 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,967 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $383.479 to a high of $383.93 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,023 | $382.74 | $2,687,977.40 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,601 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $382.47 to a high of $383.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,445 | $382.08 | $2,844,610.91 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820,624 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $381.45 to a high of $382.42 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 398 | $380.41 | $151,403.54 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 828,069 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $380.24 to a high of $380.83 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 18,000 | $67.85 | $1,221,300.00 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 828,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 20,000 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,954 Underlying: Common Stock · 20,000 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $386.40 | $38,640.00 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,467 Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,383 | $385.60 | $2,846,901.78 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,567 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $385.39 to a high of 386.34 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,477 | $384.94 | $1,723,394.29 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,950 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $384.38 to a high of $385.37 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,461 | $383.81 | $1,712,174.63 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822,487 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $383.22 to a high of $384.13 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,579 | $382.28 | $1,368,184.06 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,888 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $382.11 to a high of $382.961 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 20,000 | $67.85 | $1,357,000.00 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 28, 2020 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-016146 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,467 Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 19,940 | Not disclosed Strike: $62.00 | Not disclosed |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · derivative · entry 15 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,940 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · price: Not applicable. F11 · derivative.exercise_date: Grant of option to buy 44,535 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,379 | $384.48 | $914,680.06 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,467 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $384.28 to a high of $385.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,704 | $383.66 | $2,188,415.46 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 812,847 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $383.129 to a high of $384.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 11,857 | $382.85 | $4,539,506.99 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 818,550 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $382.099 to a high of $383.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 19,940 | $62.00 | $1,236,280.00 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 25,000 | Not disclosed Strike: $62.00 | Not disclosed |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · derivative · entry 14 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,940 Underlying: Common Stock · 25,000 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · price: Not applicable. F11 · derivative.exercise_date: Grant of option to buy 44,535 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 256 | $384.19 | $98,353.18 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,467 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $384.075 to a high of $384.225 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 128 | $382.67 | $48,982.37 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,923 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $382.51 to a high of $382.721 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,877 | $381.53 | $716,137.25 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 811,051 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $381.29 to a high of $381.845 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,816 | $380.26 | $690,550.16 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 812,928 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $379.87 to a high of $380.66 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 14,423 | $379.26 | $5,470,010.73 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 814,744 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $377.49 to a high of $378.43 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 6,300 | $377.93 | $2,380,959.00 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 829,167 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $377.49 to a high of $378.43 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.